No Record Found
No Record Found
Sector
PharmaceuticalsOpen
₹45.7Prev. Close
₹42.42Turnover(Lac.)
₹1.76Day's High
₹45.7Day's Low
₹42.8552 Week's High
₹47.952 Week's Low
₹26.69Book Value
₹18.62Face Value
₹10Mkt Cap (₹ Cr.)
63.99P/E
83.18EPS
0.51Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 13.97 | 6.53 | 6.53 | 6.53 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 11.46 | -5.31 | -5.43 | -5.3 |
Net Worth | 25.43 | 1.22 | 1.1 | 1.23 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
yoy growth (%) | 0 | 0 | 0 | 0 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | -0.05 | -0.09 | -0.07 | -0.03 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Profit before tax | -0.23 | -0.31 | 0 | -0.06 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.09 | -2.52 | -0.16 | 0.01 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | 0 | 0 |
Op profit growth | -31.43 | 166.89 | 31.01 | 18.5 |
EBIT growth | -24.06 | 15,191.52 | -96.91 | 110.74 |
Net profit growth | -24.1 | 15,171.95 | -96.92 | 110.79 |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,717.4 | 94.41 | 4,12,061.79 | 705.44 | 0.93 | 5,651.21 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,185 | 63.82 | 1,64,192.32 | 598 | 0.48 | 2,578 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,258.55 | 64.53 | 1,44,128.68 | 577 | 0.14 | 2,547 | 249.82 |
Cipla Ltd CIPLA | 1,343.35 | 23.68 | 1,08,513.22 | 616.88 | 1.19 | 4,256.93 | 411.55 |
Dr Reddys Laboratories Ltd DRREDDY | 1,285 | 23.12 | 1,07,250 | 90.6 | 0.62 | 4,266.4 | 377.56 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Director & CFO
Chaitali Kalpataru Shah
Independent Non Exe. Director
Dinesh Chander Notiyal
Independent Non Exe. Director
Avani Savjibhai Godhaniya
Independent Non Exe. Director
Vivek Mukesh Yadav
Company Sec. & Compli. Officer
Tak Bhavana Tak
G2 & G3 Samarpan Complex,
chakala Andheri East,
Maharashtra - 400099
Tel: -
Website: http://www.bacilpharma.co.in
Email: bacilpha@yahoo.com
E-2/3 Ansa Indl Est,
Saki Vihar Road, Sakinaka Andheri(E),
Mumbai - 400072
Tel: 91-22-40430200/28470
Website: www.bigshareonline.com
Email: investor@bigshareonline.com
Summary
Incorporated as a private limited company in Maharashtra in May 87, Bacil Pharma (BPL) was converted into a public limited company in Oct.90. The main business activity of the Company is Pharmaceutica...
Read More
Reports by Bacil Pharma Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.